Treatment of Clostridium difficile infection.

@article{Gerding2008TreatmentOC,
  title={Treatment of Clostridium difficile infection.},
  author={D. Gerding and C. Muto and R. Owens},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2008},
  volume={46 Suppl 1},
  pages={
          S32-42
        }
}
  • D. Gerding, C. Muto, R. Owens
  • Published 2008
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Recent outbreaks of Clostridium difficile infection (CDI) in North America have been due to a more virulent, possibly more resistant strain that causes more-severe disease, making prompt recognition of cases and optimal management of infection essential for a successful therapeutic outcome. Treatment algorithms are presented to help guide the management of patients with CDI. Metronidazole has been recommended as initial therapy since the late 1990s and continues to be the first choice for all… Expand
Antibiotic therapy for Clostridium difficile infection
TLDR
Recommendations for antibiotic treatment of Clostridium difficile infection in adults in the United States have been guided by the 2010 joint guidelines, but three new sets of guidelines became available in 2013, including one from the American College of Gastroenterology and two from Europe. Expand
Clostridium difficile infection: epidemiology, risk factors and management
TLDR
The first-line agents for CDI treatment are metronidazole and vancomycin, with the latter being the preferred agent in patients with severe disease as it has significantly superior efficacy. Expand
Can metronidazole still be used for treatment of Clostridium difficile infections?
TLDR
This review summarizes current knowledge about using metronidazole for the treatment of CDI and finds a decreased response to metronIDazole treatment ofCDI has been reported in recent years. Expand
Clostridium difficile Infections in Children
TLDR
This article reviewed recent epidemiological changes, current knowledge of virulence factors, reasonable approach to the diagnosis, and optimal treatment of CDI, and clinical guidelines for pediatric C. difficile disease. Expand
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
  • O. Cornely
  • Medicine
  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2012
TLDR
Fidaxomicin is a first-in-class, oral macrocyclic antibiotic with targeted bactericidal activity against C. difficile and minimal effect on the constituents of the normal colonic microflora in patients with CDI, and has a safety profile similar to oral vancomycin and appears generally well tolerated. Expand
Failure of Tigecycline to Treat Severe Clostridium Difficile Infection
TLDR
A 70-year-old man who developed severe Clostridium difficile infection, was admitted to the intensive care unit and eventually succumbed to complications of his illness despite receiving tigecycline for approximately three weeks in combination with vancomycin, metronidazole and intravenous immunoglobulin is reported. Expand
The changing epidemiology of Clostridium difficile infection
TLDR
CDI epidemiology continues to evolve and prompt recognition and an evidence-based treatment approach is the key to successfully manage CDI, and studies on diagnostic and therapeutic strategies are needed to further improve patient outcomes. Expand
Fecal Bacteriotherapy for the Treatment of Recurrent Clostridium Difficile Infection in Adults
TLDR
Fecal bacteriotherapy is a safe, rapid and highly effective option for the treatment of RCDI and the studies appraised in this review suggest potential for this inexpensive and minimally-risky treatment modality to undergo further investigations for clinical use. Expand
Clostridium difficile: controversies and approaches to management
TLDR
No evidence-based guidance can be given with respect to refractoriness to treatment and preventing recurrences after treatment for CDI, so results of clinical trials on new approaches with antimicrobials, immunotherapy or faecotherapy are urgently awaited. Expand
A Review of the Economics of Treating Clostridium difficile Infection
Clostridium difficile infection (CDI) is a costly result of antibiotic use, responsible for an estimated 14,000 deaths annually in the USA according to the Centers for Disease Control and Prevention.Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 129 REFERENCES
Treatment of Clostridium difficile-associated diarrhea and colitis.
  • D. Gerding
  • Medicine
  • Current topics in microbiology and immunology
  • 2000
TLDR
It is necessary to use antimicrobials judiciously in order to prevent as many cases of C. difficile diarrhea as possible and there is a need for improved treatment and prevention of this increasingly frequent and debilitating nosocomial infection. Expand
Update on Clostridium difficile
TLDR
The most dramatic change in the past several years has been the increased incidence and severity of Clostridium difficile colitis reported from multiple countries, as cases are being reported in populations not previously believed to be vulnerable. Expand
The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.
  • C. Surawicz, L. Mcfarland, +8 authors G. Elmer
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2000
TLDR
Comparison of data from this trial with data from previous studies indicates that recurrent CDD may respond to a short course of high- dose vancomycin or to longer courses of low-dose vancomYcin when either is combined with S. boulardii. Expand
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.
TLDR
The findings suggest that metronidazole and vancomycin are equally effective for the treatment of mild CDAD, but vancomYcin is superior for treating patients with severe CDAD. Expand
Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin.
TLDR
The increased cost of vancomycin compared with metronidazole for the treatment of C. difficile infection may be justifiable by reductions in the length of stay in hospital or in the need for nursing in isolation facilities, consequent upon a shorter symptomatic response time. Expand
Nitazoxanide for the treatment of Clostridium difficile colitis.
  • D. Musher, N. Logan, +4 authors J. Rossignol
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2006
TLDR
Nitazoxanide is at least as effective as metronidazole in treating C. difficile colitis, according to a prospective, randomized, double-blind study. Expand
Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy.
TLDR
A 16-year-old girl with osteogenic sarcoma whose therapy was significantly complicated by multiple relapses of CDAD is described, who was cured only after prolonged cholestyramine therapy. Expand
Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin.
TLDR
Seven patients with multiple bacteriologic and symptomatic relapses of Clostridium difficile-associated diarrhea and/or colitis were treated with vancomycin and rifampin in combination, and neither C. Difficile nor its toxin could be recovered from their stools shortly after therapy. Expand
Clostridium difficile-associated diarrhea and colitis.
  • T. Pallasch
  • Medicine
  • Journal of the California Dental Association
  • 1999
TLDR
The prevention of recurrence of CDAD by judicious use of antibiotics in its immediate posttreatment period is an important consideration and recognition of the entire spectrum of signs and symptoms of this disorder are imperative for good dental practice. Expand
Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole.
  • D. Musher, S. Aslam, +4 authors R. Hamill
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
Because of the relatively poor response to therapy, additional approaches to prevention and/or treatment of C. difficile colitis appear to be warranted. Expand
...
1
2
3
4
5
...